1 Start 2 Complete

After attending this session I can now demonstrate the identified learning objectives *

	Yes	No
Discuss the T-Cell features amenable to engineering/personalized medicine	Discuss the T-Cell features amenable to engineering/personalized medicine - Yes	Discuss the T-Cell features amenable to engineering/personalized medicine - No
Discuss the latest advances in CAR-T-Cells used in the treatment of lymphoma	Discuss the latest advances in CAR-T-Cells used in the treatment of lymphoma - Yes	Discuss the latest advances in CAR-T-Cells used in the treatment of lymphoma - No
Discuss viral specific T-Cells and their use in specific populations	Discuss viral specific T-Cells and their use in specific populations - Yes	Discuss viral specific T-Cells and their use in specific populations - No

The session format and teaching technique were appropriate for the content. *

Yes

No

This session met my expectations based on the session description and learning objectives. *

Yes

No

I observed objective, balanced content that demonstrated no bias in favor of goods or services of a commercial interest. *

Yes

No

Speaker/Moderator was engaging and provided accurate, valuable content *

	Yes	No
Elena E. Perez, MD PhD FAAAAI	Elena E. Perez, MD PhD FAAAAI - Yes	Elena E. Perez, MD PhD FAAAAI - No
Marco Ruella, MD	Marco Ruella, MD - Yes	Marco Ruella, MD - No
Michael Keller, MD	Michael Keller, MD - Yes	Michael Keller, MD - No
Daniel J. Powell, Jr., PhD	Daniel J. Powell, Jr., PhD - Yes	Daniel J. Powell, Jr., PhD - No

If you responded no to any questions, or have other comments about this session, please explain.

Please provide any additional feedback about the faculty in this session:

Leave this field blank